New therapeutic approaches to overcoming resistant EGFR exon 20 alterations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• EGFR exon 20 alterations are rare in NSCLC, leading to resistance against EGFR tyrosine kinase inhibitors (TKIs).
• These alterations include specific mutations (T790, C797S) and in-frame insertions, impacting TKI efficacy.
• Understanding these molecular changes is crucial for developing effective treatment strategies.

Purpose of the Study:

• To investigate the mechanisms of EGFR exon 20 alterations in NSCLC.
• To identify novel therapeutic strategies to overcome TKI resistance.
• To explore the role of in silico modeling in drug discovery for NSCLC.

Main Methods:

• In silico modeling of structural changes in aberrant EGFR proteins.
• Evaluation of compounds like poziotinib, cetuximab, and TAK-788 for their potential clinical activity.
• Analysis of EGFR T790M and C797S alterations and their response to targeted therapies.

Main Results:

• Poziotinib and TAK-788 demonstrated potential activity against EGFR exon 20 insertions due to their ability to access the kinase pocket.
• Cetuximab showed efficacy in attenuating dimerization caused by EGFR exon 20 insertions.
• Combined brigatinib and cetuximab showed preclinical sensitivity for EGFR C797S-mediated osimertinib resistance.

Conclusions:

• EGFR exon 20 alterations present unique challenges in NSCLC treatment.
• In silico modeling is a valuable tool for designing drugs that overcome resistance.
• Genomic interrogation combined with computational approaches can guide personalized treatment strategies for NSCLC patients.